Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naive to Pneumococcal Vaccine

Trial Profile

Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naive to Pneumococcal Vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs NBP 606 (Primary) ; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors SK Chemicals
  • Most Recent Events

    • 26 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 24 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top